Clinical Trial Update: Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Befotertinib and Icotinib for metastatic non-small cell lung cancer with uncommon EGFR mutations (G719X, L861Q, S768I).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Befotertinib
• icotinib (icotinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer Metastatic, EGFR G719X | Phase 2 | Status: RECRUITING